FDA investigating death, hospitalizations linked to mushroom-infused chocolates

USA- The Food and Drug Administration (FDA) is investigating a fatality linked to mushroom-infused sweets and chocolates from the Diamond Shruumz brand. 

The agency revealed 27 hospitalizations and 48 illnesses linked to the brand were reported as of July 1, although Poison control centers nationwide have received 82 cases of exposure to the confectionaries so far. At least 24 states have reported hospitalizations or illness linked to the brand. 

Consumers who fell ill after ingesting the mushroom-infused chocolates and sweets reported a variety of symptoms- loss of consciousness, seizures, sleepiness, confusion, abnormal heart rate, agitation, low or high blood pressure, vomiting and nausea.  

Prophet Premium blends, Diamond Shruumz’ manufacturer initiated a nationwide recall for the chocolate brand on June 27. The company acknowledged the hospitalizations, reiterating its commitment to assisting the FDA with investigations. 

The reports of the hospitalizations and death are expected to have a negative impact on the Diamon Shruumz’ brand, especially after the recall.  

The company is anticipating losses and a significant reduction in sales volume and revenue. Retailers were urged to take the products off the shelves or stop their distribution.  

Although the company advised retailers to hold the products in a secure location and ‘wait for additional instructions,’ market analysts predict it would be very difficult for the brand to restore customers’ confidence in the safety of the products in the near future.  

The company said in a statement, “It is crucial that all of our consumers refrain from ingesting this product while we, alongside the FDA, continue our investigation as to what is the cause of the serious adverse effects.” 

The news of the deaths and hospitalizations have shaken the confectionary sector in the US, especially after the infusion of psychiatric ingredients becomes more popular among confectionary consumers. The FDA’s investigation into the illnesses and death is expected to induce a paradigm shift in ingredients and labeling of such products.  

In late May, the CDC warned the public that products containing psychoactive ingredients may contain potentially harmful or undisclosed ingredients. The CDC called on the FDA and other regulators to put in place adequate regulations to protect customers against this risk.